Introduction
Over the last 2 decades, great achievements have been made regarding revascularization and cardiomyocyte protection in the management of myocardial infarction (MI) and its complications. 1 Notwithstanding, MI is still one of the leading causes of increased morbidity and mortality worldwide. A wealth of evidence from experimental and clinical studies has indicated that severe complications including cardiac rupture and post-infarction heart failure are largely or completely ascribed to inflammation in the infarcted heart. 
Inflammation following MI is driven by a myriad of invading cells and cytokines in the infarcted myocardium.
In response to myocardial injury, monocytes accumulate early and differentiate into distinct macrophage subsets. During the murine biphasic monocytes/macrophages (Mo/MU) response, the first phase (Day 1 to Day 7 after MI) is characterized by increases in Ly-6C high monocytes, and then the dominance of pro-inflammatory M1 or Ly-6C high macrophages, which are typified with properties of phagocytosis and extracellular matrix (ECM) destruction. [3] [4] [5] [6] Subsequently, the second phase begins with macrophage phenotype conversion on Day 7 after MI, when reparative M2 or Ly-6C low macrophages predominate, which contributes to resolution of inflammation and post-infarction reparative processes. 3, 7, 8 Thus, the participants of inflammatory processes not only serve as scavengers for the clearance of debris but also act as key players in the healing and regenerative processes, thereby being involved in the pathology of post-infarction ventricular remodelling (PIVR). 3, 9 In recent years, there has been a noticeable expansion of knowledge regarding the post-MI inflammatory response, including Mo/MU kinetics, maintenance, differentiation and polyfunctionality; 6, 10 this increased knowledge base has enabled clinicians to design a novel strategy targeting Mo/MU for the treatment of MI. During the exploration of agents targeting Mo/MU, our attention has focused on GABA A ergic drugs. In addition to its abundant expression in neurons, the GABA A receptor, which couples with GABA or GABA A ergic drugs, is also enriched in peripheral blood mononuclear cells. [11] [12] [13] Increasingly, the GABA A receptor has been demonstrated to play an important role in modulating inflammation or the immune response. [13] [14] [15] Further findings indicate that GABA or GABA A ergic drugs are able to modulate the T cell response mainly through the GABA A receptor of dendritic cells or macrophages in experimental autoimmune encephalomyelitis (EAE), 16 suggesting the emerging role of Mo/MU as targets of GABA or GABA A ergic drugs. Therefore, we reasoned that through the GABA A receptor expressed on Mo/MU, GABA A ergic drugs could modulate post-infarction inflammation.
To address the role of the GABA A receptor expressed on Mo/MU after MI, we designed and performed a study by treating MI mice with a specific GABA A receptor antagonist or agonist. In this study, we found that activation or blockade of the GABA A receptor signalling in Mo/MU can produce a skewed monocyte or macrophage subset after MI, resulting in a series of altered events after MI, including cardiac rupture, adverse ventricular remodelling, and cardiac dysfunction.
Methods
For detailed experimental procedures, see Supplementary materials online.
Experiment design
Our studies were designed to address the role of the GABA A receptor through its specific agonist, topiramate, and antagonist, bicuculline to modulate Mo/MU response in mice with MI. To examine the effect of GABA A ergic drugs on mice after MI, except mice in Sham group, MIoperated mice were randomly assigned to one of the following treatments: (i) phosphate-buffered saline (PBS)-treated group (control), PBS at 8ml/kg; (ii) topiramate-treated group, topiramate at 35mg/kg; (iii) bicucullinetreated group, bicuculline at 2 mg/kg. All drugs (provided by Sigma-Aldrich, USA) were given 6 h after MI intraperitoneally (i.p.) once a day consecutively for 14 days. Mice were euthanized using carbon dioxide (CO 2 ), according to AVMA Guidelines for the Euthanasia of Animals. Next, in studies to deplete Mo/MU from mice, PBS and clodronate-containing liposomes [ClodronateLiposomes.org (9 March 2017, date last accessed)] were used for control or Mo/MU depletion experiments, respectively. MIoperated mice predictively received either PBS liposomes as control group or clodronate liposomes which were randomly assigned to one of the following treatments: (i) clodronate liposomes and PBS-treated group, PBS at 8ml/kg; (ii) clodronate liposomes and topiramate-treated group, topiramate at 35mg/kg; and (iii) clodronate liposomes and bicuculline-treated group, bicuculline at 2mg/kg. All drugs were given 6 h after MI i.p. once a day consecutively until mice were euthanized. PBS liposomes or clodronate liposomes (35 lg/g) 1 day before and 1, 3, and 6 days after MI as described previously. 17 The treatment assignments were predetermined, and each animal was assigned a code number, which was not broken until the completion of the full protocol. Thus, the left ventricular (LV) function, immunological, histological, and molecular biological measurements described herein were performed in a blinded fashion. Sample sizes for each protocol and experimental measurement are provided in the figure legend, as appropriate. Each experiment was performed a minimum of three times, with some performed up to five times.
Echocardiography
Serial closed chest transthoracic echocardiography was performed on 1, 7, 14, and 28 days post-MI. Anaesthesia was induced via nosecone inhalation and administration of 2% isoflurane gas while the temperature of animals was maintained at 36.5-37.5 C. Upon reaching the echocardiographic plane of anaesthesia, the isoflurane concentration was adjusted to 0.75-1%. Images were obtained using a Vevo 2100 high-resolution imaging system equipped with a 30-MHz transducer (VisualSonics, Canada) as previously described. 18 All measurements were analysed off-line by blinded observers using the Vevo2100 workstation software and each measurement reported was an average of eight cardiac cycles. LV enddiastolic diameter (LVID ED ) and LV end-systolic diameter (LVID ES ) were obtained from M-mode tracings from parasternal short-axis views at the mid and apical levels at each time point. Fractional shortening (FS) was calculated as % FS = (LVID ED -LVID ES )/LVID ED Â100%. Parasternal longaxis scans were used to provide additional data on LV end-diastolic volume (LVEDV) and LV end-systolic volume (LVESV). The formula of left ventricular ejection fraction (LVEF) percentage is [(EDV-ESV)/ EDV] Â 100%, (end-diastolic volume, EDV; end-systolic volume, ESV).
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End diastole was measured at the time of the apparent maximal LV diastolic dimension, and end systole was measured at the time of the most anterior systolic excursion of the posterior wall.
Statistical analysis
All data are presented as means ± SEM. Multiple group comparisons were analysed by one-way analysis of variance, followed by Bonferroni's test. The survival rate was analysed by Kaplan-Meier survival analysis and compared by the log-rank test. Rupture rates were analysed by Fisher's exact test. GraphPad Prism 6.0 (GraphPad Software) and SPSS 21.0 (SPSS Inc.) were used for all these analyses. A two-sided P < 0.05 was considered statistically significant. To identify target cells of GABA A ergic drugs after MI, it is necessary to investigate the distribution of the GABA A receptor in the myocardium. We first sought to detect expression of the constituent a 1 -and b 3 -subunits of the GABA A receptor at the mRNA and protein levels, and we found that the a 1 -and b 3 -subunits of the GABA A receptor were absent in adult or neonatal mouse cardiomyocytes, fibroblasts and adult vascular endothelial cells ( Figure 1A and B). Consistent with previous findings in humans or BALB/c mice, 11, 20 both the a 1 -and b 3 -subunits were detected in macrophages and neutrophils in C57BL/6 mice; in comparison, only the a 1 -subunit was found to be expressed in peripheral blood monocytes, spleen monocytes, Th1 cells, and Th2 cells ( Figure 1C and D). The GABA A ergic drugs in our study included one specific agonist or antagonist of the GABA A receptor (topiramate or bicuculline, respectively). ) in the bone marrow, spleen, peripheral blood and heart by flow cytometry (FCM) on Days 1, 3, and 7 post-MI. The results showed that GABA A ergic drugs exerted no influence on neutrophil counts in the peripheral blood and heart on Days 1, 3, and 7 post-MI (see Supplementary material online, Figure S1) Next, we sought to determine the cause of the reduced or increased Ly-6C high monocytes counts in topiramate-or bicuculline-treated MI mice, respectively. The spleen has been shown to be a major site of a sustained boost in monocytopoiesis 23, 24 while the process is regulated by IL-1b. 10, 25 Along with the peripheral Ly-6C high monocyte numbers, IL-1b levels were detected in the infracted myocardium, serum, spleen, and bone marrow to assess the influence of GABA A ergic drugs on splenic monocytopoiesis. We found that IL-1b expression was down-or upregulated in topiramate-or bicuculline-treated MI mice, respectively ( Figure 2G ), which was in agreement with the respective reduction or increase in the peripheral blood and splenic Ly-6C high monocyte numbers.
We also investigated the effect of GABA A ergic drugs on monocyte mobilization from the bone marrow and a splenic reservoir after MI. Ly-
6C
high monocytes mobilize and enter the infarct via surface chemokine receptor 2 (CCR2) coupled with chemoattractant protein (MCP)-1. 9, 26 We found that neither topiramate nor bicuculline treatment altered either MCP-1 expression levels (see Supplementary material online, Figure  S5A ) or the total and Ly-6C high monocyte numbers in the bone marrow (see Supplementary material online, Figure S5B ). Thus, GABA A ergic drug treatment exerts no influence on monocyte mobilization from the bone marrow after MI. Taken together, GABA A ergic drugs impact monocyte recruitment by regulating splenic monocytopoiesis after MI.
3.3 Topiramate causes a macrophage subset skewing towards the M2 or Ly-6C low macrophage phenotype after MI To assess the effect of GABA A ergic drugs on the differentiation of monocytes into macrophages and on the macrophage phenotype conversion after MI, we analysed total macrophage numbers and M1/M2 or Ly-6C high /Ly-6C low macrophage subpopulations/percentages in the infarcted myocardium. First, we used specific macrophage markers (Mac-3
to detect the total numbers of macrophages in the infarcted myocardium by using immunohistochemistry or FCM. Surprisingly, we found that there was no significant change in the total macrophage numbers between the controls and GABA A ergic drug treatment on Days 3 and 7 post-MI (see Supplementary material online, Figure S6 ), which appears to be disproportionate to numbers of cardiac macrophages derived from the observed influx of monocytes into the infarcted myocardium.
Given that a certain quantity of endogenous foetal derived macrophages capable of phagocytosis and angiogenesis exist in the myocardium, [27] [28] [29] our results suggest that these cells as another supply of macrophages might be involved in the Mo/MU response to MI. We identified foetal derived macrophages (CD45 Figure S7 ).
Then we analysed Figure 3C , F, and G, see Supplementary material online, Figure S9 ). The results indicate that GABA A ergic drugs can modulate macrophage phenotype conversion, thereby yielding a skewed macrophage subset after MI.
We performed in vitro studies to explore whether GABA A ergic drugs directly modulate this macrophage phenotype conversion. We found that GABA A ergic drugs failed to affect either M1 or M2 macrophage polarization directly (see Supplementary material online, Figure S10 ).
Topiramate decreases proinflammatory M1 or Ly-6C
high macrophage activities after MI By detecting expression of M1 or Ly-6C high macrophage-producing orrelated cytokines involved in the first phase after MI, we could assess the effects of GABA A ergic drugs on M1 or Ly-6C high macrophage activities. In line with the decreased trend of M1 or Ly-6C high macrophage numbers, topiramate significantly down-regulated the expression of tumour necrosis factora (TNF-a), IL-6 and matrix metalloproteinase (MMP)-9 as well as decreased MMP-9 activity (Figure 4) , which is responsible for destroying the ECM. 30 These data contrasted with the results from the bicuculline treatment.
Topiramate promotes infarct healing mediated by M2 or Ly-6C low macrophages after MI
We also investigated the expression of M2 or Ly-6C low macrophageproducing or -related cytokines that contribute to the resolution of inflammation, angiogenesis, and collagen deposition during the reparative processes after MI. 4, 7 Accompanied by alterations of M2 or Ly-6C low macrophage numbers, GABA A ergic drug treatment exerted significant effects on the production of IL-10, vascular endothelial growth factor (VEGF) and transforming growth factor-b 1 (TGF-b 1 ) ( Figure 5A ). Consequently, compared with controls, topiramate-treated MI mice exhibited more neovascularization as determined by immunofluorescence staining for CD31 þ endothelial cells, more reparative a-smooth muscle actin þ (a-SMA þ ) and vimention þ myofibroblasts and increased collagen I deposition ( Figure 5B -E), all of which strengthens infarct healing quality. 31, 32 These data contrasted with the results from the bicuculline treatment. Figure S6A ). We performed serial echocardiography on MI mice. Within 1 day after MI, each group had similar results regarding echocardiographic indices and infarct size as determined by TTC staining (see Supplementary material online, Figure S12A and Table S1 ). As expected, GABA A ergic drug treatment significantly affected the cardiac function of MI mice as reflected by indices such as left ventricular EF%, FS%, EDV, and ESV. At 14 days and 28 days post-MI, compared with controls, topiramate treatment showed an improvement of EF%, FS% and increased left ventricular myocardial contractility. This treatment also resulted in a smaller EDV, ESV. By contrast, MI mice that underwent bicuculline treatment showed exacerbated left ventricular dysfunction ( Figure 6F and Table 1 , see Supplementary material online, Figure S11F and Table S2 ).
Topiramate reduces mortality and rupture rates after MI
In the context of post-infarction inflammation having a direct relationship with MI prognosis, 9 we hypothesized that GABA A ergic drugs could influence the surrogate clinical outcomes of MI mice. Therefore, we performed continuous monitoring for 28 days post-MI of mortality and rupture rates of MI mice treated with or without GABA A ergic drugs. Compared with controls, topiramate-treated MI mice suffered less death rates (14.5% vs. 28.9%), whereas bicuculline-treated MI mice had increased mortality (29.1% vs. 28.9%) ( Figure 6G) . Furthermore, topiramate-treated MI mice had less rupture rates (12.5% vs. 69.2%) ( Figure 6H) . Thus, this effective decrease in rupture rates could contribute to the reduced mortality of topiramate-treated MI mice. By contrast, the increased mortality in bicuculline-treated MI mice might be due to increased rupture rates (96.3% vs. 69.2%). In the murine permanent occlusion model, cardiac rupture normally occurs between days 3 to 7 after MI as previously described. 30 Interestingly, our results show that topiramate can effectively reduce rupture rates from Days 1 to 5, Collectively, these findings indicate that GABA A ergic drugs can exert a significant influence on cardiac function and surrogate clinical outcomes after MI.
3.8 Topiramate shows no effect on the improvement of cardiac dysfunction and surrogate clinical outcomes after MI with depletion of monocytes or macrophages Given that the GABA A receptor is not merely enriched in Mo/MU, we cannot exclude the possibility that GABA A ergic drugs can exert an influence on cardiac function and surrogate clinical outcomes directly or greatly through the GABA A receptor expressed in other cells (e.g. nerve cells through which it modulates the central nerve system (CNS)-heart axis or other inflammatory cells like neutrophils). Thus, we designed experiments to investigate whether GABA A ergic drugs would be able to affect cardiac function and surrogate clinical outcomes in the setting of selective depletion of Mo/MU via administration of clodronate liposomes, which causes the apoptosis of Mo/MU. 17, 33 Treatment with clodronate-containing liposomes significantly depleted Mo/MU from the spleen and heart (see Supplementary material online, Figure S13 ). After mice were pretreated with clodronate liposomes and underwent ligation of the left anterior descending coronary artery, neither topiramate nor bicuculline treatment showed any significant or additional change in the peripheral monocyte, cardiac macrophage (see Supplementary material online, Figure S13 ) and neutrophil counts (see Supplementary material online, Figure S14 ). And there was no significant alteration of Th2 polarization skewing in GABA A ergic drug treated MI mice whether depletion of Mo/MU or not (see Supplementary material online, Figures S15 and S17). Compared with MI mice pretreated with clodronate liposomes, neither topiramate nor bicuculline was able to attenuate or exacerbate PIVR (as reflected by reduced collagen content and unaffected infarct size when monocytes and macrophages were depleted, Figure 7A -C and see Supplementary material online, Figure S18) , cardiac function or the surrogate clinical outcomes of MI mice ( Figure 7D-F and Table 2 ). These data further demonstrate that GABA A ergic drugs influence cardiac function and surrogate clinical outcomes primarily by targeting Mo/MU after MI.
Discussion
Since the 1970s, when the role of GABA was confined to an inhibitory transmitter in the CNS, GABA A ergic drugs (the GABA A receptor agonists or antagonists) have been developed and extensively applied in the treatment of nervous system diseases. 21, 22 In recent years, emerging evidence has shown that GABA A ergic drugs are able to function as immunomodulators in vitro or in vivo. 13, 14, 16, 34 Our work provides evidence for the first time that, through a specific agonist or antagonist (topiramate or bicuculline) of the GABA A receptor which is not enriched in myocardium but Mo/MU, selective modulation of Mo/MU activities can exert a distinct influence on cardiac function and the surrogate clinical outcomes in MI mice. In a pro and con manner, we found that GABA A ergic drugs can potently modulate post-infarction inflammation by acting upon Mo/ MU. In the presence of Mo/MU, topiramate-treated MI mice showed the greatest improvement in cardiac rupture, mortality, PIVR and cardiac function, whereas bicuculline-treated MI mice showed the worst indices. By contrast, with depletion of Mo/MU in MI mice, neither topiramate nor bicuculline exhibited any influence on surrogate clinical outcomes, PIVR and cardiac dysfunction, indicating that these GABA A ergic drugs target Mo/MU in MI. The observed improvements or exacerbations were found due to regulation of key inflammatory processes including splenic monocytopoiesis and focal macrophage polarization after MI. Therefore, with its novel pharmacological properties, topiramate has emerged as a promising agent for the treatment of MI. The novel pharmacological properties of topiramate enable it to balance the inflammatory and anti-inflammatory response. We herein present our findings that topiramate exerts its ability to modulate the Ly-6C Topiramate exhibited its ability to down-regulate IL-1b level, decrease pro-inflammatory Ly-6C high monocyte numbers, promote the conversion from the M1 to M2 or Ly-6C high to Ly-6C low macrophage phenotype and preserve foetal derived macrophages after MI. With novel insight into the role of Mo/MU response involved in postinfarction inflammation, Mo/MU dominate inflammatory cell infiltration and act as pivotal modulators of the inflammatory response to balance myocardial injury and repair. 3, 5, 9 Though either elevated monocyte counts or depletion of monocytes exerts distinct pro-inflammatory effects on myocardial injury, both events result in impaired infarct healing. Hearts experiencing either of these scenarios present insufficient accumulation of ECM and impaired collagen cross-linking. 17, 40 Generally, collagen I correlates with thick fibres that would be expected to increase the tensile strength of the heart, 41 thus blunting thinning and dilatation of the infarcted region (infarct expansion) 42 and protecting against MI induced ventricular rupture and death. 43, 44 Underpinning these benefits, PIVR is attenuated and cardiac function is improved. However, an unfavourable reparative macrophage phenotype with the consequence of excess collagen deposition results in overactive fibrosis in the remote zone, [45] [46] [47] which is one hallmark of adverse PIVR. 3 Thus it is important to influence macrophage phenotype rather than simply changing its numbers/function. Our results showed that topiramate reduced infarct size while enhancing neovascularization surrounding the infarct and collagen density in the infarcted area, but not in the remote zone. In parallel, the relative collagen I content increased within the infarcted region. Thus, topiramate attenuates adverse PIVR by orchestrating Mo/MU response to balance myocardial injury and repair.
In conclusion, we provide a novel target to modulate post-infarction inflammation. Owing to rescue abilities of the administration of a clinically applicable dosage of topiramate, 48 we present a promising drug that with mouse Ly-6C low monocytes. 5, 6 In addition, the expression profile and binding site of the murine GABA A receptor correspond to the human analogue. Thus, by studying the murine immune system (which is extensively used in scientific research) we can still gain more information regarding the GABA A receptor and GABA A ergic drugs in modulating cardiac recovery after MI.
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